Email updates

Keep up to date with the latest news and content from BMC Cancer and BioMed Central.

Open Access Research article

Prognostic significance of the expression of GFRα1, GFRα3 and Syndecan-3, proteins binding ARTEMIN, in mammary carcinoma

Zheng-Sheng Wu12, Vijay Pandey3, Wen-Yong Wu4, Shan Ye2, Tao Zhu1* and Peter E Lobie35*

Author Affiliations

1 Hefei National Laboratory for Physical Sciences at Microscale and School of Life Sciences, University of Science and Technology of China, Hefei, Anhui, People's Republic of China

2 Department of Pathology, Anhui Medical University, Hefei, Anhui, People's Republic of China

3 Cancer Science Institute of Singapore and Department of Pharmacology, National University of Singapore, Centre for Life Sciences, #03-06C, 28 Medical Drive, Singapore, 117456, Singapore

4 Department of General Surgery, First Affiliated Hospital of Anhui Medical University, Anhui, Hefei, Anhui, People's Republic of China

5 National Cancer Science Institute of Singapore, National University Health system, Singapore, Singapore

For all author emails, please log on.

BMC Cancer 2013, 13:34  doi:10.1186/1471-2407-13-34

Published: 26 January 2013

Additional files

Additional file 1: Table S1:

Matrix of the Spearman’s correlations between ARTN expression and either GFRα1, GFRα3 and SDC3 mRNA or protein expression in mammary carcinoma (n = 159). Table S2 Co-expression of ARTN with GFRα1, GFRα3 or SDC3 protein in mammary carcinoma patients (n = 159). Table S3 Association of tumor GFRα1, GFRα3 and SDC3 expression with five year relapse free (RFS) and overall survival (OS) in patients with mammary carcinoma. Table S4 Multivariate analysis of tumor GFRα1, GFRα3 and SDC3 expression with five year relapse free (RFS) and overall survival (OS) in patients with mammary carcinoma. Table S5 Association of tumor GFRα1, GFRα3 and SDC3 expression with five year relapse free (RFS) and overall survival (OS) in patients with ER-positive mammary carcinoma. Table S6 Association of tumor ARTN, GFRα1, GFRα3 and SDC3 expression with five year relapse free (RFS) and overall survival (OS) in patients with ER negative mammary carcinoma. Table S7 Association of tumor GFRα1, GFRα3 and SDC3 expression with five year relapse free (RFS) and overall survival (OS) in patients with HER2-negative mammary carcinoma. Table S8 Association of tumor ARTN, GFRα1, GFRα3 and SDC3 expression with five year relapse free (RFS) and overall survival (OS) in patients with HER2-positive mammary carcinoma. Table S9 Association of tumor ARTN, GFRα1, GFRα3 and SDC3 expression with five year relapse free (RFS) and overall survival (OS) in patients with mammary carcinoma. Table S10 Multivariate analysis of tumor ARTN, GFRα1, GFRα3 and SDC3 expression with five year relapse free (RFS) and overall survival (OS) in patients with mammary carcinoma.

Format: DOC Size: 215KB Download file

This file can be viewed with: Microsoft Word Viewer

Open Data